Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Items 101–200 of 617
Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy
Cerezo, M., & Rocchi, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03175-5 · Cited by 125
Dyikanov, D., Zaitsev, A., Васильева, Т. В., Wang, I., Sokolov, A. A., Bolshakov, E. S., Frank, A., Turova, P., Golubeva, O., Gantseva, A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.008 · Cited by 122
Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 122
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 120
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
Xue, G., Romano, E., Massi, D., & Mandalà, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.009 · Cited by 120
Self-citationChevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Hennart, B., Allorge, D., van Geel, N., Gele, M. V., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.982382 · Cited by 119
Myeloid regulatory cells in tumor spreading and metastasis
Keskinov, A. A., & Shurin, M. R. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.07.017 · Cited by 116
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2015) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Li, T., Liu, T., Zhu, W., Xie, S., Zhao, Z., Feng, B., Guo, H., & Yang, R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211035540 · Cited by 114
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 114
Tomić, S., Joksimović, B., Bekić, M., Vasiljević, M., Milanović, M., Čolić, M. J., & Vučević, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00475 · Cited by 114
MDSCs in cancer: Conceiving new prognostic and therapeutic targets
Sanctis, F. D., Solito, S., Ugel, S., Molon, B., Bronte, V., & Marigo, I. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.001 · Cited by 111
Chen, H.-M., Ma, G., Gildener‐Leapman, N., Eisenstein, S. G., Coakley, B. A., Ozao, J. J., Mandeli, J., Divino, C. M., Schwartz, M., Sung, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2742 · Cited by 108
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Curti, B. D., Koguchi, Y., Leidner, R. S., Rolig, A. S., Sturgill, E. R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B. M., Hilgart-Martiszus, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002371 · Cited by 108
Liu, H., Zeng, X., Ren, X., Zhang, Y., Huang, M., Tan, L., Dai, Z., Lai, J., Xie, W., Chen, Z., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327230 · Cited by 106
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 104
Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 101
Wang, Z., Zhang, L., Wang, H., Xiong, S., Li, Y., Tao, Q., Xiao, W., Qin, H., Wang, Y., & Zhai, Z. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1646-4 · Cited by 100
Involvement of local renin‐angiotensin system in immunosuppression of tumor microenvironment
Nakamura, K., Yaguchi, T., Ohmura, G., Kobayashi, A., Kawamura, N., Iwata, T., Kiniwa, Y., Okuyama, R., & Kawakami, Y. (2017) · Cancer Science · doi:10.1111/cas.13423 · Cited by 100
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 100
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Colton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo, S., Tong, L., Chong, J., Liu, Y., Xu, J., Oliveira, M. M. S., Chen, Y., Chen, Z., Lee, K., Burduli, N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2952 · Cited by 98
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4574 · Cited by 97
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet, G., Brown, M., Bozkus, C. C., & Bhardwaj, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210164 · Cited by 97
Koh, J., Kim, Y., Lee, K. Y., Hur, J. Y., Kim, M. S., Kim, B., Cho, H. J., Lee, Y. C., Bae, Y. H., Ku, B. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048534 · Cited by 97
Tietze, J. K., Angelova, D., Heppt, M. V., Reinholz, M., Murphy, W. J., Spannagl, M., Ruzicka, T., & Berking, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.031 · Cited by 94
DeVito, N. C., Sturdivant, M. S., Thievanthiran, B., Xiao, C., Plebanek, M. P., Salama, A. K. S., Beasley, G. M., Holtzhausen, A., Novotny‐Diermayr, V., Strickler, J. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109071 · Cited by 93
Chen, G., Gupta, R., Petrik, S., Laiko, M., Leatherman, J. M., Asquith, J. M., Daphtary, M. M., Garrett-Mayer, E., Davidson, N. E., Hirt, K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0058 · Cited by 93
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro de Erauso, L., Zuazo, M., Arasanz, H., Bocanegra, A., Hernandez, C., Fernandez, G., Garcia-Granda, M. J., Blanco, E., Vera, R., Kochan, G., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00441 · Cited by 91
Bjoern, J., Nitschke, N. J., Iversen, T. Z., Schmidt, H., Fode, K., & Svane, I. M. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1100788 · Cited by 91
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 89
Meirow, Y., Kanterman, J., & Baniyash, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00523 · Cited by 89
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 89
Gauttier, V., Pengam, S., Durand, J., Biteau, K., Mary, C., Morello, A., Néel, M., Porto, G., Teppaz, G., Thépenier, V., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135528 · Cited by 88
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
Koh, J., Hur, J. Y., Lee, K. Y., Kim, M. S., Heo, J. Y., Ku, B. M., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76130-1 · Cited by 87
Clinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 87
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
French, J. D. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0398-9 · Cited by 86
Raphael, I., Kumar, R., McCarl, L. H., Shoger, K. E., Wang, L., Sandlesh, P., Sneiderman, C. T., Allen, J., Zhai, S., Campagna, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637146 · Cited by 86
Lin, S., Zhang, X., Huang, G., Cheng, L., Lv, J., Zheng, D., Lin, S., Wang, S., Wu, Q., Long, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01605-4 · Cited by 86
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Jessurun, C. A. C., Vos, J. A. M., Limpens, J., & Luiten, R. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00233 · Cited by 82
Granhøj, J. S., Jensen, A. W. P., Presti, M., Met, Ö., Svane, I. M., & Donia, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2064711 · Cited by 82
Wistuba‐Hamprecht, K., Martens, A., Haehnel, K., Foppen, M. G., Yuan, J. D., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dréno, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.001 · Cited by 82
Self-citationBiomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 81
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed Central · Cited by 80
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
Harkus, U., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.005 · Cited by 79
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Gele, M. V., van Geel, N., & Brochez, L. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0376-x · Cited by 79
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 78
Bailur, J. K., Gueckel, B., Derhovanessian, E., & Pawelec, G. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0541-z · Cited by 78
Heterogeneous Myeloid Cells in Tumors
Dou, A., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13153772 · Cited by 78
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Monocyte programming by cancer therapy
Patysheva, M. R., Frolova, A. A., Larionova, I., Afanas’ev, S. G., Тарасова, А. С., Чердынцева, Н. В., & Kzhyshkowska, J. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994319 · Cited by 75
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
Tumor-Mediated Neutrophil Polarization and Therapeutic Implications
Raftopoulou, S., Valadez-Cosmes, P., Mihalič, Z. N., Schicho, R., & Kargl, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063218 · Cited by 75
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Evaluating biomarkers in melanoma
Karagiannis, P., Fittall, M. W., & Karagiannis, S. N. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00383 · Cited by 74
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
Kitano, S., Nakayama, T., & Yamashita, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00270 · Cited by 72
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 72
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 70
Singh, L., Muise, E. S., Bhattacharya, A., Grein, J., Javaid, S., Stivers, P., Zhang, J., Qu, Y., Joyce-Shaikh, B., Loboda, A., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0622 · Cited by 70
Proia, T. A., Singh, M., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1066 · Cited by 70
A clinical and biological perspective of human myeloid-derived suppressor cells in cancer
Shipp, C., Speigl, L., Janssen, N., Martens, A., & Pawelec, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2278-y · Cited by 69
Youn, J., Park, S.-M., Park, S., Kim, G., Lee, H., Son, J., Hong, M. H., Ghaderpour, A., Baik, B., Islam, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65666-x · Cited by 69
Carril-Ajuria, L., Desnoyer, A., Meylan, M., Dalban, C., Naigeon, M., Cassard, L., Vano, Y. A., Rioux-Leclercq, N. C., Chouaïb, S., Beuselinck, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004885 · Cited by 69
Vijayakumar, G., Palese, P., & Goff, P. H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.032 · Cited by 69
The tumor organismal environment: Role in tumor development and cancer immunotherapy
Dieterich, L. C., & Bikfalvi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.021 · Cited by 68
Immunobiology of cholangiocarcinoma
Tomlinson, J. L., Valle, J. W., & Ilyas, S. I. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.010 · Cited by 67
Autoantibodies as Potential Biomarkers in Breast Cancer
Qiu, J., Keyser, B., Lin, Z., & Wu, T. (2018) · Biosensors · doi:10.3390/bios8030067 · Cited by 66
Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti, R., Chiarion‐Sileni, V., & Mandruzzato, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249559 · Cited by 65
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4118 · Cited by 65
de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 65
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Ortiz‐Cuaran, S., Bouaoud, J., Karabajakian, A., Fayette, J., & Saintigny, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614332 · Cited by 65
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 64
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 64
Self-citationVISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 64
Jiang, J., Guo, W., & Liang, X. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.09.025 · Cited by 62
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets
Szebeni, G. J., Vízler, C., Nagy, L. I., Kitajka, K., & Puskás, L. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111958 · Cited by 62
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
Improving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C., Spilgies, L., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 61
Laborde, R. R., Lin, Y., Gustafson, M. P., Bulur, P. A., & Dietz, A. B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00147 · Cited by 61
Nigam, S., McCarl, L. H., Kumar, R., Edinger, R. S., Kurland, B. F., Anderson, C. J., Panigrahy, A., Kohanbash, G., & Edwards, W. B. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01427-1 · Cited by 61
Liang, M., Liu, Y., Zhang, Z., Yang, H., Dai, N., Zhang, N., Sun, W. Y., Guo, Y., Kong, J., Wang, X., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2061045 · Cited by 60
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Baxter, M. A., Middleton, F., Cagney, H. P., & Petty, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01425-7 · Cited by 59
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Meirow, Y., & Baniyash, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2035-6 · Cited by 59
Shigeta, K., Kosaka, T., Kitano, S., Yasumizu, Y., Miyazaki, Y. J., Mizuno, R., Shinojima, T., Kikuchi, E., Miyajima, A., Tanoguchi, H., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5354-5 · Cited by 59
Emerging immunotherapy for the treatment of esophageal cancer
Oh, S. J., Han, S., Lee, W., & Lockhart, A. C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1163336 · Cited by 58
Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression
Cheng, J., Yuan, Y., Zhu, B., & Jia, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740827 · Cited by 58
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.